Yuflyma®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasis
Psoriasic arthritis
Ankylosing spondylitis
Uveitis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
DATE:
31/03/2021
STATUS:
Authorized